| Autor: |
Hubble J; Ohio State University Parkinson's Disease Center, Columbus 43210, USA., Koller WC, Atchison P, Taylor AC, Citerone DR, Zussman BD, Friedman CJ, Hawker N |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical pharmacology [J Clin Pharmacol] 2000 Jun; Vol. 40 (6), pp. 641-6. |
| Abstrakt: |
The objectives of this study were to measure the pharmacokinetics of ropinirole at steady state when the drug is used as an adjunct to L-dopa and evaluate the long-term tolerability of ropinirole in this indication. Twenty-four patients who were taking L-dopa for Parkinson's disease and experiencing a lack of symptomatic control were recruited. Patients received open-label adjunctive treatment with ropinirole for up to 2 years. The starting dose was 0.5 mg bid, which could be titrated to a maximum of 6.0 mg tid. Ropinirole demonstrated approximately dose-linear pharmacokinetics at steady state; corresponding values were higher during tid than bid dosing. A reduction in mean L-dopa dose was maintained throughout the trial. The combination of L-dopa and ropinirole was generally well tolerated, with only 1 patient withdrawing from treatment because of adverse events. Thus, ropinirole shows approximately linear steady-state pharmacokinetics and a good safety profile when administered with L-dopa. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text